Seminars in Diagnostic Pathology
Volume 25, Issue 2 , Pages 120-125 , May 2008

Serological reagents for the immunohistochemical analysis of melanoma metastases in sentinel lymph nodes

  • Achim A. Jungbluth, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Achim A. Jungbluth, MD, PhD, Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, Z-1503, Box 32, New York, NY 10021.

References 

  1. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 1998;32:139–146
  2. Granter SR, Weilbaecher KN, Quigley C, et al. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol. 2002;10:47–51
  3. Kaufmann O, Koch S, Burghardt J, et al. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740–746
  4. Kucher C, Zhang PJ, Acs G, et al. Can Melan-A replace S-100 and HMB-45 in the evaluation of sentinel lymph nodes from patients with malignant melanoma?. Appl Immunohistochem Mol Morphol. 2006;14:324–327
  5. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205–211
  6. Busam KJ, Iversen K, Coplan KC, et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol. 2001;25:197–204
  7. Granter SR, Weilbaecher KN, Quigley C, et al. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am J Dermatopathol. 2001;23:185–189
  8. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta. 1999;1450:191–231
  9. Cross SS, Hamdy FC, Deloulme JC, et al. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology. 2005;46:256–269
  10. Salama I, Malone PS, Mihaimeed F, et al. A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008;34:357–364
  11. Takahashi K, Isobe T, Ohtsuki Y, et al. Immunohistochemical study on the distribution of alpha and beta subunits of S-100 protein in human neoplasm and normal tissues. Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45:385–396
  12. Timar J, Udvarhelyi N, Banfalvi T, et al. Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies. Histopathology. 2004;44:180–184
  13. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637–668
  14. Zubovits J, Buzney E, Yu L, et al. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol. 2004;35:217–223
  15. Martinez-Penuela A, Del OJ, Boan JF, et al. Incidental findings in negative sentinel lymph nodes of patients with malignant melanoma: report of three cases. Am J Dermatopathol. 2007;29:104–105
  16. Vanstapel MJ, Gatter KC, de Wolf-Peeters C, et al. New sites of human S-100 immunoreactivity detected with monoclonal antibodies. Am J Clin Pathol. 1986;85:160–168
  17. Gown AM, Vogel AM, Hoak D, et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123:195–203
  18. Adema GJ, de Boer AJ, van't Hullenaar R, et al. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb (HMB-50, and HMB-45 are encoded by a single cDNA). Am J Pathol. 1993;143:1579–1585
  19. Adema GJ, de Boer AJ, Vogel AM, et al. Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem. 1994;269:20126–20133
  20. Theos AC, Truschel ST, Raposo G, et al. The silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res. 2005;18:322–336
  21. Sundram U, Harvell JD, Rouse RV, et al. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol. 2003;16:802–810
  22. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54:196–200
  23. Satzger I, Volker B, Meier A, et al. Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am J Surg Pathol. 2007;31:1175–1180
  24. Granter SR, Weilbaecher KN, Quigley C, et al. Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation. Mod Pathol. 2001;14:6–9
  25. Bonetti F, Pea M, Martignoni G, et al. False-positive immunostaining of normal epithelia and carcinomas with ascites fluid preparations of antimelanoma monoclonal antibody HMB45. Am J Clin Pathol. 1991;95:454–459
  26. Hornick JL, Fletcher CD. PEComa: what do we know so far?. Histopathology. 2006;48:75–82
  27. Plaza JA, Suster D, Perez-Montiel D. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol. 2007;15:421–425
  28. Yaziji H, Gown AM. Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol. 2003;11:11–15
  29. de Vries TJ, Smeets M, de Graff R, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy (A study conducted by the EORTC Melanoma Cooperative Group). J Pathol. 2001;193:13–20
  30. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: an anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595–602
  31. Murray CA, Leong WL, McCready DR, et al. Histopathological patterns of melanoma metastases in sentinel lymph nodes. J Clin Pathol. 2004;57:64–67
  32. Reinke S, Koniger P, Herberth G, et al. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma. Am J Dermatopathol. 2005;27:401–406
  33. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol. 1997;9:681–683
  34. Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175–208
  35. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180:35–42
  36. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91:3515–3519
  37. Fernandes BF, Odashiro AN, Saraiva VS, et al. Immunohistochemical expression of melan-A and tyrosinase in uveal melanoma. J Carcinog. 2007;6:6
  38. Shidham VB, Qi D, Rao RN, et al. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with ‘MCW melanoma cocktail’: a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. BMC Cancer. 2003;3:15
  39. Chen YT, Stockert E, Jungbluth A, et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A. 1996;93:5915–5919
  40. Kawakami Y, Battles JK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods. 1997;202:13–25
  41. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol. 1996;19:192–205
  42. Fetsch PA, Cormier J, Hijazi YM. Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. J Immunother. 1997;20:60–64
  43. Busam KJ, Jungbluth AA. Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol. 1999;6:12–18
  44. Shidham VB, Qi DY, Acker S, et al. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45. Am J Surg Pathol. 2001;25:1039–1046
  45. Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976–982
  46. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22:57–63
  47. Deavers MT, Malpica A, Ordonez NG, et al. Ovarian steroid cell tumors: an immunohistochemical study including a comparison of calretinin with inhibin. Int J Gynecol Pathol. 2003;22:162–167
  48. Stewart CJ, Nandini CL, Richmond JA. Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol. 2000;53:206–211
  49. Yao DX, Soslow RA, Hedvat CV, et al. Melan-A (A103) and inhibin expression in ovarian neoplasms. Appl Immunohistochem Mol Morphol. 2003;11:244–249
  50. Busam KJ, Kucukgol D, Sato E, et al. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol. 2005;29:400–406
  51. Nonaka D, Laser J, Tucker R, et al. Immunohistochemical evaluation of necrotic malignant melanomas. Am J Clin Pathol. 2007;127:787–791
  52. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, et al. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer. 2004;100:1683–1691
  53. Kwon BS. Pigmentation genes: the tyrosinase gene family and the pmel 17 gene family. J Invest Dermatol. 1993;100(suppl):134S–140S
  54. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178:489–495
  55. Chen YT, Stockert E, Tsang S, et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci U S A. 1995;92:8125–8129
  56. Jungbluth AA, Iversen K, Coplan K, et al. T311–an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract. 2000;196:235–242
  57. McNutt NS, Urmacher C, Hakimian J, et al. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity. J Cutan Pathol. 1995;22:502–517
  58. Barrow C, Browning J, MacGregor D, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006;12:764–771
  59. Orchard GE. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J. 2000;32:475–481
  60. Hofbauer GF, Kamarashev J, Geertsen R, et al. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol. 1998;25:204–209
  61. Gajjar NA, Cochran AJ, Binder SW. Is MAGE-1 expression in metastatic malignant melanomas really helpful?. Am J Surg Pathol. 2004;28:883–888
  62. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer. 1998;75:517–524
  63. Fuse N, Yasumoto K, Takeda K, et al. Molecular cloning of cDNA encoding a novel microphthalmia-associated transcription factor isoform with a distinct amino-terminus. J Biochem. 1999;126:1043–1051
  64. Udono T, Yasumoto K, Takeda K, et al. Structural organization of the human microphthalmia-associated transcription factor gene containing four alternative promoters. Biochim Biophys Acta. 2000;1491:205–219
  65. Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 2000;14:1712–1728
  66. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006;12:406–414
  67. Amae S, Fuse N, Yasumoto K, et al. Identification of a novel isoform of microphthalmia-associated transcription factor that is enriched in retinal pigment epithelium. Biochem Biophys Res Commun. 1998;247:710–715
  68. King R, Weilbaecher KN, McGill G, et al. Microphthalmia transcription factor (A sensitive and specific melanocyte marker for melanoma diagnosis). Am J Pathol. 1999;155:731–738
  69. King R, Googe PB, Weilbaecher KN, et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 2001;25:51–57
  70. Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391:298–301
  71. Miller AJ, Du J, Rowan S, et al. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res. 2004;64:509–516
  72. Busam KJ, Woodruff JM, Erlandson RA, et al. Large plaque-type blue nevus with subcutaneous cellular nodules. Am J Surg Pathol. 2000;24:92–99
  73. Jungbluth AA, King R, Fisher DE, et al. Immunohistochemical and reverse transcription-polymerase chain reaction expression analysis of tyrosinase and microphthalmia-associated transcription factor in angiomyolipomas. Appl Immunohistochem Mol Morphol. 2001;9:29–34
  74. Seethala RR, Goldblum JR, Hicks DG, et al. Immunohistochemical evaluation of microphthalmia-associated transcription factor expression in giant cell lesions. Mod Pathol. 2004;17:1491–1496
  75. Zavala-Pompa A, Folpe AL, Jimenez RE, et al. Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and renal and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers. Am J Surg Pathol. 2001;25:65–70
  76. Takeda K, Yasumoto K, Kawaguchi N, et al. Mitf-D, a newly identified isoform, expressed in the retinal pigment epithelium and monocyte-lineage cells affected by Mitf mutations. Biochim Biophys Acta. 2002;1574:15–23
  77. Rochaix P, Lacroix-Triki M, Lamant L, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol. 2003;16:481–490
  78. Vennegoor C, Hageman P, Van Nouhuijs H, et al. A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol. 1988;130:179–192
  79. MacKie RM, Campbell I, Turbitt ML. Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J Clin Pathol. 1984;37:367–372
  80. Vennegoor C, Calafat J, Hageman P, et al. Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C-3. Int J Cancer. 1985;35:287–295
  81. Cohen-Knafo E, Al ST, Aziza J, et al. Production and characterisation of an antimelanoma monoclonal antibody KBA 62 using a new melanoma cell line reactive on paraffin wax embedded sections. J Clin Pathol. 1995;48:826–831
  82. Kocan P, Jurkovic I, Boor A, et al. Immunohistochemical study of melanocytic differentiation antigens in cutaneous malignant melanoma (A comparison of six commercial antibodies and one non-commercial antibody in nodular melanoma, superficially spreading melanoma and lentigo maligna melanoma). Cesk Patol. 2004;40:50–56
  83. Trefzer U, Rietz N, Chen Y, et al. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res. 2000;292:583–589
  84. Thomson TM, Mattes MJ, Roux L, et al. Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermatol. 1985;85:169–174
  85. Trefzer U, Chen Y, Herberth G, et al. The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma. BMC Cancer. 2006;6:8
  86. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med. 1990;171:1375–1380
  87. Baisden BL, Askin FB, Lange JR, et al. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol. 2000;24:1140–1146
  88. Boi S, Cristofolini P, Togni R, et al. Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk. Melanoma Res. 2002;12:147–153
  89. Gutzmer R, Kaspari M, Brodersen JP, et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology. 2002;41:510–518
  90. Li W, Stall A, Shivers SC, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg. 2000;231:795–803
  91. Spanknebel K, Coit DG, Bieligk SC, et al. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol. 2005;29:305–317
  92. Starz H. Pathology of the sentinel lymph node in melanoma. Semin Oncol. 2004;31:357–362
  93. Denninghoff VC, Kahn AG, Falco J, et al. Sentinel lymph node: detection of micrometastases of melanoma in a molecular study. Mol Diagn. 2004;8:253–258
  94. Eudy GE, Carlson GW, Murray DR, et al. Rapid immunohistochemistry of sentinel lymph nodes for metastatic melanoma. Hum Pathol. 2003;34:797–802
  95. Shidham VB, Chang CC, Komorowski R. MCW melanoma cocktail for the evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma. Expert Rev Mol Diagn. 2005;5:281–290
  96. Lohmann CM, Iversen K, Jungbluth AA, et al. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma. Am J Surg Pathol. 2002;26:1351–1357

PII: S0740-2570(08)00028-2

doi: 10.1053/j.semdp.2008.05.002

Seminars in Diagnostic Pathology
Volume 25, Issue 2 , Pages 120-125 , May 2008

Article Tools